Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy

References

• Marret G, Borcoman E, Le Tourneau C. Pembrolizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2019;19(9):871–877.
   PubMed Web of Science ®Google Scholar
• Stevanovic S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–1550.
   PubMed Web of Science ®Google Scholar
• Stevanovic S, Pasetto A, Helman SR, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200–205.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965.
   PubMed Web of Science ®Google Scholar
• Gong MN, Bajwa EK, Thompson BT, Christiani DC. Body mass index is associated with the development of acute respiratory distress syndrome. Thorax. 2010;65(1):44–50.
   PubMed Web of Science ®Google Scholar
• Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37(17):1470–1478.
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856–1867.
   PubMed Web of Science ®Google Scholar
• Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122–139.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109–1119.e1110.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qian L, Chen K, et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response. Mol Ther Oncolytics. 2022;25:31–42.
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018;36(17):1658–1667.
   PubMed Web of Science ®Google Scholar
• Mell LK, Brumund KT, Daniels GA, et al. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma. Clin Cancer Res. 2017;23(19):5696–5702.
   PubMed Web of Science ®Google Scholar
• Zhang R, Cui Y, Guan X, Jiang X. A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: a Retrospective Cohort Study. Front Oncol. 2021;11:752504.
   PubMed Web of Science ®Google Scholar
• Lin XJ, Li QJ, Lao XM, Yang H, Li SP. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer. 2015;15:707.
   PubMed Web of Science ®Google Scholar
• Zhang QN, Li Y, Zhao Q, et al. Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: a case report. Thorac Cancer. 2021;12(10):1617–1619.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q, Liu Z, et al. Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: a Retrospective Study. Front Oncol. 2022;12:877155.
   PubMed Web of Science ®Google Scholar
• Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371–375.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: national Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020;38(33):3883–3894.
   PubMed Web of Science ®Google Scholar
• Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2018;28(4):641–655.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Monk BJ, Vergote I, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386(6):544–555.
   PubMed Web of Science ®Google Scholar
• Xu Q, Wang J, Sun Y, et al. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: a Multicenter, Single-Arm, Prospective Phase II Trial. J Clin Oncol. 2022;40(16):1795–1805.
   PubMed Web of Science ®Google Scholar
• Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374(6573):1325–1326.
   PubMed Web of Science ®Google Scholar
• Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Rev Drug Discovery. 2022;21(7):529–540.
   PubMed Web of Science ®Google Scholar
• Huang X, He M, Peng H, et al. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J Immunother Cancer. 2021;9(5).
   Web of Science ®Google Scholar
• Tamura K, Hasegawa K, Katsumata N, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label Phase 2 trial. Cancer Sci. 2019;110(9):2894–2904.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021;39(2):154–173.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:6349):409–413.
   Web of Science ®Google Scholar
• Zhang L, Luo M, Yang H, Zhu S, Cheng X, Qing C. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients. J Ovarian Res. 2019;12(1):19.
   PubMedGoogle Scholar
• Zou R, Xu H, Li F, Wang S, Zhu L. Increased Expression of UBE2T Predicting Poor Survival of Epithelial Ovarian Cancer: based on Comprehensive Analysis of UBE2s, Clinical Samples, and the GEO Database. DNA Cell Biol. 2021;40(1):36–60.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang Y, Hang C. Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer. Ann Translational Med. 2022;10(6):337.
   PubMed Web of Science ®Google Scholar
• Park E, Kim SW, Kim S, et al. Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. Mod Pathol. 2021;34(3):637–646.
   PubMed Web of Science ®Google Scholar
• Prieske K, Alawi M, Oliveira-Ferrer L, et al. Genomic characterization of vulvar squamous cell carcinoma. Gynecol Oncol. 2020;158(3):547–554.
   PubMed Web of Science ®Google Scholar
• Liu J, Li Z, Lu T, et al. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China. BMC Med Genomics. 2022;15(1):231.
   PubMed Web of Science ®Google Scholar
• Saito Y, Takasawa A, Takasawa K, et al. Aldolase A promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma. Cancer Sci. 2020;111(8):3071–3081.
   PubMed Web of Science ®Google Scholar
• Tian W, Zhou J, Chen M, et al. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity. Sci Rep. 2022;12(1):11632.
   PubMed Web of Science ®Google Scholar
• Wei X, Sha Y, Wei Z, et al. Bi-allelic mutations in DNAH7 cause asthenozoospermia by impairing the integrality of axoneme structure. Acta Biochim Biophys Sin (Shanghai). 2021;53(10):1300–1309.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu L, Shen Q, et al. Loss of function mutation in DNAH7 induces male infertility associated with abnormalities of the sperm flagella and mitochondria in human. Clin Genet. 2022;102(2):130–135.
   PubMed Web of Science ®Google Scholar
• Van Duzer A, Taniguchi S, Elhance A, Tsujikawa T, Oshimori N. ADAP1 promotes invasive squamous cell carcinoma progression and predicts patient survival. Life Science Alliance. 2019;2(6):67.
   Web of Science ®Google Scholar
• Liu H, Zhao H. Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma. Neoplasma. 2019;66(3):487–493.
   PubMed Web of Science ®Google Scholar
• van der Lely L, Häfliger J, Montalban-Arques A, et al. Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. Inflammatory Intestinal Dis. 2019;4(4):161–173.
   PubMedGoogle Scholar
• Jariwala N, Mendoza RG, Garcia D, et al. Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: implications for Hepatocellular Carcinoma. Hepatology commun. 2019;3(9):1258–1270.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Miyamoto T, Higuchi S, et al. cDNA expression library screening revealed novel functional genes involved in clear cell carcinogenesis of the ovary in vitro. J Obstet Gynaecol. 2021;41(1):100–105.
   PubMedGoogle Scholar
• Springwald A, Lattrich C, Skrzypczak M, Goerse R, Ortmann O, Treeck O. Icb-1 Gene expression is elevated in human endometrial adenocarcinoma and is closely associated with HER2 expression. Cancer Invest. 2010;28(9):904–909.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
   PubMed Web of Science ®Google Scholar
• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–334.
   PubMed Web of Science ®Google Scholar
• de Bruin EC, Taylor TB, Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med. 2013;5(11):101.
   PubMedGoogle Scholar
• Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP. Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol. 2006;301:259–281.
   PubMed Web of Science ®Google Scholar
• Huang X, He M, Peng H, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–384.
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Porter VL, Zong Z, et al. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat Genet. 2020;52(8):800–810.
   PubMed Web of Science ®Google Scholar
• Christensen S, Van der Roest B, Besselink N, et al. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat Commun. 2019;10(1):4571.
   PubMedGoogle Scholar